Close Menu

NEW YORK – Organ transplant diagnostics company CareDx announced today that it has formed a strategic partnership with NanoString Technologies to develop HistoMap, a gene expression profiling test to identify allograft rejection in transplant biopsy tissue.

Under the terms of the agreement, CareDx will combine its expertise and transplant registries with NanoString's nCounter platform, and its newly introduced Human Organ Transplant panel — a 770-gene panel designed to evaluate human immune response following organ transplantation.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.